IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference
IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on developing immune-modulatory therapeutic cancer vaccines, has announced its participation in two upcoming investor conferences. The company's leadership team, including CEO Mai-Britt Zocca, CFO Amy Sullivan, and CMO Qasim Ahmad, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Summit on May 27, 2025. Additionally, Dr. Zocca will present at the Jefferies Global Healthcare Conference on June 4, 2025, where the team will also conduct one-on-one investor meetings.
IO Biotech (IOBT), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di vaccini terapeutici oncologici immuno-modulatori, ha annunciato la sua partecipazione a due prossimi convegni per investitori. Il team dirigenziale dell'azienda, incluso il CEO Mai-Britt Zocca, il CFO Amy Sullivan e il CMO Qasim Ahmad, parteciperà a una tavola rotonda informale al TD Cowen 6th Annual Oncology Summit il 27 maggio 2025. Inoltre, la Dott.ssa Zocca terrà una presentazione al Jefferies Global Healthcare Conference il 4 giugno 2025, dove il team condurrà anche incontri individuali con gli investitori.
IO Biotech (IOBT), una compañía biofarmacéutica en etapa clínica enfocada en el desarrollo de vacunas terapéuticas contra el cáncer moduladoras del sistema inmunológico, ha anunciado su participación en dos próximas conferencias para inversores. El equipo directivo de la empresa, incluyendo a la CEO Mai-Britt Zocca, la CFO Amy Sullivan y el CMO Qasim Ahmad, participará en una charla informal en el TD Cowen 6th Annual Oncology Summit el 27 de mayo de 2025. Además, la Dra. Zocca presentará en la Jefferies Global Healthcare Conference el 4 de junio de 2025, donde el equipo también llevará a cabo reuniones individuales con inversores.
IO Biotech (IOBT)는 면역 조절 치료용 암 백신 개발에 주력하는 임상 단계의 바이오제약 회사로, 두 건의 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. CEO 마이-브리트 조카, CFO 에이미 설리반, CMO 카심 아흐마드 등 경영진이 2025년 5월 27일 TD Cowen 6th Annual Oncology Summit에서 파이어사이드 채팅에 참여합니다. 또한 조카 박사는 2025년 6월 4일 Jefferies Global Healthcare Conference에서 발표를 진행하며, 팀은 1:1 투자자 미팅도 진행할 예정입니다.
IO Biotech (IOBT), une société biopharmaceutique en phase clinique spécialisée dans le développement de vaccins thérapeutiques anticancéreux à modulation immunitaire, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'équipe dirigeante de l'entreprise, comprenant la CEO Mai-Britt Zocca, la CFO Amy Sullivan et le CMO Qasim Ahmad, participera à une discussion informelle lors du TD Cowen 6th Annual Oncology Summit le 27 mai 2025. De plus, le Dr Zocca présentera lors du Jefferies Global Healthcare Conference le 4 juin 2025, où l'équipe tiendra également des réunions individuelles avec des investisseurs.
IO Biotech (IOBT), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung immunmodulatorischer therapeutischer Krebsimpfstoffe spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Führungsteam des Unternehmens, darunter CEO Mai-Britt Zocca, CFO Amy Sullivan und CMO Qasim Ahmad, wird am TD Cowen 6th Annual Oncology Summit am 27. Mai 2025 an einem Fireside-Chat teilnehmen. Zusätzlich wird Dr. Zocca am Jefferies Global Healthcare Conference am 4. Juni 2025 präsentieren, wo das Team auch Einzelgespräche mit Investoren führen wird.
- None.
- None.
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that Mai-Britt Zocca, PhD, the company’s President and CEO, along with Amy Sullivan, the company’s CFO, and Qasim Ahmad, MD, the company’s CMO, will be participating in a fireside chat at the TD Cowen 6th Annual Oncology Summit: Insights for ASCO & EHA being held virtually May 27-28, 2025. Additionally, Dr. Zocca will be presenting and Dr. Zocca, Amy Sullivan, and Dr. Ahmad will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 3-5, 2025 in New York, NY.
Fireside Chat Details
Date and Time: Tuesday, May 27, 2025, 10:30 AM EST
Participants: Mai-Britt Zocca, PhD, President & CEO, Amy Sullivan, CFO, Qasim Ahmad, MD, CMO
Webcast Link: https://wsw.com/webcast/cowen180/iobt/2014758
Presentation Details
Date and Time: Wednesday, June 4, 2025, 7:35 AM EST
Presenter: Mai-Britt Zocca, PhD, President & CEO
Webcast Link: https://wsw.com/webcast/jeff319/iobt/1853008
The webcast replay for the fireside chat and the presentation will be available from the Investors section of the company’s website at https://investors.iobiotech.com for 90 days.
About Cylembio®
Cylembio® (imsapepimut and etimupepimut, adjuvanted) is an investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine candidate designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase 1 (IDO1) positive and/or programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating Cylembio in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating Cylembio in combination with pembrolizumab as first line treatment in patients with advanced solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating Cylembio in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors. Enrollment in the three ongoing company-sponsored clinical trials is now complete.
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio.
Cylembio® is a registered trademark of IO Biotech ApS, a subsidiary of IO Biotech.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the expected timing of the top-line data from, or outcome of, the company’s Phase 3 trial, the timing regarding submission of a BLA, the timing regarding launch of Cylembio, the timing or outcome of other current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Edelman
917-498-1967
julie.funesti@edelman.com
FAQ
When is IO Biotech (IOBT) presenting at the Cowen Oncology Summit 2025?
Who will represent IO Biotech at the Jefferies Global Healthcare Conference 2025?
Where can investors watch IO Biotech's conference presentations?
What type of company is IO Biotech (IOBT)?
